Could the mechanosensitive GPR133 receptor pathway be safely and effectively targeted in humans perhaps using a specific activator like AP503, to provide a superior, long-lasting therapeutic strategy for bone formation and osteoporosis reversal that avoids the severe side effects or lack of efficacy associated with current drugs?